Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria
Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria
复制标题
DOI：
10.1128/iai.72.11.6492-6502.2004
复制
发表时间：
2004-11-01
影响因子：
3.1
通讯作者：
McBride, JS
中科院分区：
文献类型：
--
作者：
Cavanagh, DR;Dodoo, D;McBride, JS
这项纵向前瞻性研究表明，恶性疟原虫裂殖子表面蛋白1（MSP-1）的N-末端阻断2区域的抗体与加纳稳定但季节性疟疾传播地区的临床疟疾保护有关。在主要疟疾传播季节开始之前，在280名儿童的队列中测量MSP-1第2区的抗体。然后，在17个月的时间里，从临床和寄生虫学角度对这一组进行积极的疟疾监测。有证据表明，抗体反应块2和随后的临床疟疾的风险显着降低之间的关联。此外，统计生存分析提供了关于随时间推移的效应持续时间的新信息。结果支持了这样的结论：MSP-1的第2区是针对恶性疟原虫的保护性免疫的靶点，因此是开发疟疾疫苗的有希望的新候选者。
This longitudinal prospective study shows that antibodies to the N-terminal block 2 region of the Plasmodium falciparum merozoite surface protein 1 (MSP-1) are associated with protection against clinical malaria in an area of stable but seasonal malaria transmission of Ghana. Antibodies to the block 2 region of MSP-1 were measured in a cohort of 280 children before the beginning of the major malaria transmission season. The cohort was then actively monitored for malaria, clinically and parasitologically, over a period of 17 months. Evidence is presented for an association between antibody responses to block 2 and a significantly reduced risk of subsequent clinical malaria. Furthermore, statistical survival analysis provides new information on the duration of the effect over time. The results support a conclusion that the block 2 region of MSP-1 is a target of protective immunity against P. falciparum and, thus, a promising new candidate for the development of a malaria vaccine.